today announced the publication of results from a clinical trial with nadunolimab in combination with pembrolizumab in the journal Investigational New Drugs. 15 heavily pre-treated patients with solid ...

One continuing challenge is the need to suppress transplant patients' immune systems to prevent their bodies from rejecting ...

With current CDC leadership waiting for Senate confirmation, the Advisory Committee's vaccination recommendations may be approved by Health Secretary Robert F. Kennedy Jr instead. HealthDay News ...

See reviews below to learn more or submit your own review. Gillette has been producing shaving products and personal care items since 1901. Its offerings include razors, blades and grooming ...

PD-1/PD-L1 immune checkpoint inhibitors are effective in dMMR cancers, and are approved in advanced solid cancers characterized ... patients could prevent clinical recurrence,” said Janjigian.

The FDA has placed another clinical hold on a gene therapy for Duchenne muscular dystrophy developed by Solid Biosciences, pulverising its share price. The halt of the IGNITE DMD trial was ...

today announced that the first patient has been treated in its Phase 1 clinical trial evaluating PHST001, an anti-CD24 macrophage checkpoint inhibitor, in patients with advanced solid tumors.

of RB-164™ in participants with hematologic cancers such as lymphoma and advanced solid tumors that are associated with high ROR-1 expression. The Phase 1 clinical trial initiates with dose ...